Home » Newsletters » BioWorld Science

BioWorld Science

July 27, 2004

View Archived Issues

Assessment of the pharmacokinetics and pharmacodynamics of UK-427857

New beta-secretase inhibitors prepared and tested at GSK

Incyte researchers present novel chemokine CCR2/CCR5 antagonists

Novel tachykinin NK3 antagonists with potential in CNS conditions

Actelion claims new sulfamide-based endothelin antagonists

Novel cannabinoid CB2 agonists under study at Sanofi-Synthelabo

Isis scientists describe new anti-HCV agents targeting IRES

Novel protein kinase inhibitors and their use in cancer therapy

Update on the safety and pharmacokinetics of SRA-333

Therapeutic benefits found with rosiglitazone in patients with early AD

Clinical data support the development of immunotherapeutic strategies for AD

New 12-week labeling information approved for Seroquel

Abbott and Deltanoid to develop fourth generation active D therapies

KaloBios inlicenses antibody drug candidate for autoimmune diseases

FDA approves Alinia tablets for adults

Seed financing round at TheraQuest supports progression of TQ-1015

Gene Logic acquires technology program from Millennium

Hemispherx Biopharma accelerates development of Alferon N

New phase II biomarker trial for SGN-15

Fast track status for subcutaneous icatibant in HAE

Pivotal trial cleared for Liberte paclitaxel-eluting coronary stent

New study evaluates effects of chromium picolinate in pre-diabetes patients

Potent and selective FXa inhibitors reported by Pfizer

Promising antiarthritic effects for methionine aminopeptidase-2 inhibitor

Novel anti-prion agent effective against experimental scrapie in vivo

Specific oral PI3K inhibitor blocks neutrophil trafficking and activation in vivo

Ezetimibe/simvastatin approved by FDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...